Welcome to our dedicated page for Context Therapeutics news (Ticker: CNTX), a resource for investors and traders seeking the latest updates and insights on Context Therapeutics stock.
Context Therapeutics Inc. (CNTX) is a clinical-stage biopharmaceutical company focused on T cell engaging (TCE) bispecific antibodies for solid tumors. The CNTX news feed on Stock Titan aggregates company press releases and related coverage so readers can follow how its pipeline and corporate activities evolve over time.
According to recent announcements, Context is advancing three key programs: CTIM-76, a Claudin 6 x CD3 TCE in a Phase 1 dose-escalation trial for CLDN6-positive ovarian, endometrial, and testicular cancers; CT-95, a Mesothelin x CD3 TCE in a Phase 1 study for mesothelin-expressing solid tumors such as pancreatic, non-small cell lung, ovarian, mesothelioma, and colorectal cancers; and CT-202, a Nectin-4 x CD3 TCE in preclinical development with pH-dependent activity designed for the tumor microenvironment. News items often highlight clinical enrollment updates, early safety and anti-tumor activity signals, and preclinical data presented at major oncology meetings.
Investors and followers of CNTX can also see updates on quarterly operating and financial results, at-the-market equity program changes, Nasdaq listing compliance notices and resolutions, and organizational developments such as inducement stock option grants and senior leadership appointments. The company regularly reports participation in scientific and investor conferences, including ASCO, AACR, SITC, and healthcare investment forums, which can signal upcoming data disclosures or corporate visibility efforts.
Use this page to review Context Therapeutics’ latest clinical, financial, and corporate news in one place. For those tracking immuno-oncology and T cell engager developments in solid tumors, the CNTX news stream provides a consolidated view of the company’s reported progress and key milestones.
Context Therapeutics (NASDAQ: CNTX) has appointed Dr. Karen Chagin as Chief Medical Officer, effective June 9, 2025. Dr. Chagin brings significant expertise in T cell therapy development, having previously served as Senior Vice President at Adaptimmune where she contributed to the approval of Tecelra®, the first engineered cell therapy approved for solid tumors in the U.S. She also held the CMO position at Tmunity before its acquisition by Kite Pharma.
Dr. Chagin succeeds interim CMO Dr. Karen Smith, who will remain on the Company's Board. As part of her employment agreement, Dr. Chagin will receive an inducement grant of 153,000 stock options, vesting over four years, with an exercise price set at the closing price on her employment start date.
Context Therapeutics (Nasdaq: CNTX), a clinical-stage biopharmaceutical company focused on T cell engaging bispecific antibodies for solid tumors, has granted inducement stock options to two new employees. The grants total 160,000 shares of common stock, awarded outside the company's 2021 Long-Term Performance Incentive Plan. The options were granted on May 5 and May 12, 2025, with exercise prices of $0.839 and $0.78 per share respectively. These 10-year options vest over four years, with 25% vesting after the first year and the remainder vesting monthly over the following three years, contingent on continued employment.
Context Therapeutics (NASDAQ: CNTX) announced a leadership transition as Dr. Karen Smith takes over as interim Chief Medical Officer (CMO), replacing Dr. Claudio Dansky Ullmann who will depart on May 10, 2025. Dr. Smith, currently a Board member, will serve in a dual capacity while the company searches for a permanent CMO.
Dr. Smith brings over 20 years of experience in drug development and commercialization, having previously served as Global Head of R&D and CMO at Jazz Pharmaceuticals, with additional senior leadership roles at Allergan, AstraZeneca, and Bristol Myers Squibb. She will oversee the company's clinical development programs during this transition period.
Context Therapeutics presented preclinical and translational data for their cancer treatment candidate CT-95 at the 2025 AACR Annual Meeting in Chicago. CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody designed to treat solid tumors.
Key findings from the preclinical studies show that CT-95:
- Selectively binds to mesothelin-expressing cells
- Targets a unique membrane-proximal region of mesothelin
- Avoids impact of shed mesothelin sink
- Demonstrates high activity and good tolerance in various models
- Activates T cells without broad cytokine release
The company has already begun Phase 1 clinical trials and expects to share initial clinical data by mid-2026. The treatment targets mesothelin expressing cancers, including pancreatic, ovarian, and mesothelioma, addressing a significant unmet medical need.
Context Therapeutics (CNTX) has initiated dosing in the Phase 1 clinical trial of CT-95, a mesothelin x CD3 T cell engaging bispecific antibody. CT-95 targets mesothelin-expressing cancers, which are present in approximately 30% of all cancers. This marks Context's second active clinical trial in 2025, following the CTIM-76 trial launched earlier this year.
The Phase 1 trial (NCT06756035) is designed as an open-label, dose escalation and expansion study to evaluate CT-95's safety and efficacy in patients with mesothelin-expressing advanced solid tumors, including ovarian, pancreatic, lung, and mesothelioma cancers. The dose escalation portion is expected to enroll up to 30 patients, with initial data anticipated in mid-2026.
The study will assess safety, tolerability, pharmacokinetics, and anti-tumor activity metrics including overall response rate, duration of response, and disease control rate.
Context Therapeutics (Nasdaq: CNTX), a clinical-stage biopharmaceutical company focused on T cell engaging bispecific antibodies for solid tumors, has announced its participation in multiple upcoming investor conferences in April and May 2025.
The company will participate in four major events:
- Stifel Virtual Targeted Oncology Forum (April 8-9) featuring a presentation on April 8 at 10:00 AM ET
- Jones Healthcare and Technology Innovation Conference in Las Vegas (April 8-9)
- 24th Annual Needham Virtual Healthcare Conference (April 7-10)
- Citizens Life Sciences Conference in New York City (May 7-8) with a presentation on May 8 at 2:30 PM ET
The company will conduct one-on-one meetings during all conferences.
Context Therapeutics (Nasdaq: CNTX), a clinical-stage biopharmaceutical company focused on T cell engaging bispecific antibodies for solid tumors, has announced an upcoming poster presentation at the AACR Annual Meeting 2025 in Chicago (April 25-30, 2025).
The presentation will feature data on CT-95, the company's clinical asset targeting mesothelin x CD3 TCE. The poster will specifically detail the selection methodology for the first-in-human dose of CT-95, utilizing the minimal anticipated biological effect level (MABEL) approach. The research supports a proposed clinical starting dose of 0.1 μg/kg for CT-95.
Context Therapeutics (CNTX) reported its full year 2024 financial results and business highlights. The company ended 2024 with $94.4 million in cash, expected to fund operations into 2027. Key developments include the first patient dosed with CTIM-76 in January 2025 for CLDN6-positive cancers, acquisition of CT-95, and in-licensing of CT-202.
Financial results show R&D expenses increased to $22.7 million in 2024 from $17.8 million in 2023, primarily due to $14.75 million in research charges related to CT-95 acquisition and CT-202 licensing. The company reported a net loss of $26.7 million for 2024, compared to $24.0 million in 2023.
Upcoming milestones include first patient dosing for CT-95 in Q2 2025, initial CTIM-76 clinical data in H1 2026, and CT-95 trial data in mid-2026.
Context Therapeutics (Nasdaq: CNTX), a biopharmaceutical company focused on solid tumor treatments, has granted stock options to two new employees as employment inducements. The grants total 46,000 shares of common stock, awarded outside the company's 2021 Long-Term Performance Incentive Plan, complying with Nasdaq Rule 5635(c)(4).
The options were granted on February 18 and 24, 2025, with exercise prices of $0.83 and $0.8314 per share respectively, matching Context's closing stock prices on those dates. These 10-year options follow a four-year vesting schedule: 25% vests after one year, with the remaining 75% vesting in 36 monthly installments. Vesting is contingent on continued employment with Context.